Maria Dêbiec‐Rychter

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 899 citations

Medicine, Molecular Genetics, Oncology +14

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Florian Rambow, Aljosja Rogiers, Oskar Marín-Béjar et al. · Cell · 2018 · 771 citations · Full text

Medicine, Dermatology, Oncology +12

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

George D. Demetri, Robert S. Benjamin, Charles D. Blanke et al. · Journal of the National Comprehensive Cancer Network · 2007 · 636 citations

Medicine, Oncology, Radiation Oncology +13

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 494 citations · Full text

Medicine, Oncology, Pharmacology +15

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Grant A. McArthur, George D. Demetri, A. van Oosterom et al. · Journal of Clinical Oncology · 2005 · 481 citations

Medicine, Oncology, Pathology +17